Frede Donskov

Clinical Professor in Oncology, University Hospital of Southern Denmark, Esbjerg, Denmark.

[Frede Donskov @FDonskov]

Well-written and insightful paper every oncologist and clinician with frontline clinical workload should read - before burnout

[soria @jsoriamd]

Oncology is a demanding profession, asking a great amount of those practicing in the field. Oncology clinicians can set boundaries while still meeting ethical practice standards. Setting boundaries may ultimately allow clinicians to be more present & engaged while working, have more satisfaction with their work, & maintain personal well-being. Some great suggestions in this table & article https://t.co/oVqeXt1Qgz

[Brian Rini, MD @brian_rini]

Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides durability. We need a way to harness the benefits of both approaches. @montypal @DrChoueiri @tompowles1 @motzermd @HHammersMD

[Frede Donskov @FDonskov]

Any suggestions for a training scheme @HowardGurney ?

[Howard Gurney @HowardGurney]

We need comprehensive training schemes for trial coordinators and move beyond the current apprentice scheme. Experienced trial coordinators are in short supply and we need to stop poaching each others

[Niels Them Kjær @NielsThem]

Flere kvitter, når prisen på cigaretter ryger i vejret. Men prisen skal hoppe, så det kan mærkes - ellers har det ingen effekt. Så hjælp @sophieloehde og sundheden, @JeppeBruus:
Sæt prisen højt op, så vi kan få en #røgfrifremtid
#dkpol #sundpol
https://t.co/VknaBl5m59

[Tom Powles @tompowles1]

I thought only astronauts, bond villains and tech billionaires appeared in TIME magazine. Some people are all 3 but David McDermott is certainly none of the above and still made it! @Uromigos https://t.co/PlkHB90vjB

[Milan Hora @milanhoraplzen]

Cytoreductive nephrectomy associated with longer OS in patients with #mRCC treated with immune checkpoint inhibitor (ICI) therapy in any line of therapy. A multicenter retrospective cohort study of 367 patients (CN+ST 232, ST alone 135). https://t.co/dqM8I5VWai

[Frede Donskov @FDonskov]

https://t.co/F06p1twTHw

[Aaron Ginn @aginnt]

The new Prime Minister of Italy.

Wow. https://t.co/fkKTM8I9Fs

[Frede Donskov @FDonskov]

Very excited to see our work on molecular analysis in Clear Cell & Non-Clear Cell Real-World #Renal Cell Carcinoma just published in @actaoncol

Thanks to great collaborative effort w co-authors

https://t.co/RTAdpyipe3

@OncoAlert @DrChoueiri @montypal @brian_rini @TSteiniche

[Frede Donskov @FDonskov]

@KidneyCancer Sad news. Nicholas Vogelzang was a pioneer, a true leader, and a nice person!

[Myriam Chalabi @MyriamChalabi]

About the smile: the standing ovation also meant that people saw what I knew: behind every one of these bars is a patient. I know every name and have seen almost everyone. I know their stories and their children. And I believe many are cured because of this. #ESMO22 #ChalabiPlot

[Frede Donskov @FDonskov]

Awesome discussion!

[Sumanta K. Pal, MD, FASCO @montypal]

Hello to those waking up on the west coast! Had a chance to discuss @DrChoueiri's outstanding presentation of #COSMIC313 at #ESMO22 in the presidential session. Here's a quick synopsis. 1st, what an AMAZING mtg this has been for #kidneycancer (slide credit: @ZeynepZengin) (1/10)

[Toni Choueiri, MD @DrChoueiri]

A waterfall plot or a tidal wave 🌊???? 🤩 😯

99% pathologic response with nivo/ipi in dMMR CRC and NO disease recurrences!!

#ESMO22 ⁦@myESMO⁩ ⁦@MyriamChalabi⁩

[Aly-Khan Lalani @lalaniMD]

#ESMO22 Presidential symposium - adjuvant nivo/ipi in #RCC by @motzermd:
- 15% pT2a g3/4, pT2b
- 5% sarcomatoid (pdl1 status pending)
- placebo arm 24-mos DFS rate 74% (note 67% in KN-564)
- 1 in 3 d/c due to drug tox
@DrChoueiri @montypal @neerajaiims @BradMcG04 @OncoAlert

[Frede Donskov @FDonskov]

Great summary @montypal on adjuvant therapy in #renalcellcarcinoma

[Sumanta K. Pal, MD, FASCO @montypal]

Grateful to @TheLancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex at #ESMO22. It's interesting to envision how this data impacts current landscape (link below): (1/10) https://t.co/F5Y5HyNaxY

[Rana McKay, MD, FASCO @DrRanaMcKay]

Mid week reset! @TylerSbrt @AdamSharpMedOnc @DrChoueiri

[Toni Choueiri, MD @DrChoueiri]

Our 30-month #KYN564 adjuvant RCC trial is published @TheLancetOncol —led by @tompowles1, presented #GU22 @ASCO —Note HR 0.63 improved from 0.68, all subgroups HR<1, AND if we remove M1NED/N+/T4=> HR 0.68. Still significant/clinically relevant @OncoAlert

https://t.co/HEyyZLDQP3

[Vishal Navani, MD @navstruck]

Our @IMDConline paper outlining #cabozantinib activity post #immunotherapy combination treatment in #kcsm #kidneycancer is out in @ElsevierConnect Clinical Genitourinary Cancers..1/6🧵

https://t.co/BpfTr5jTFT

[Frede Donskov @FDonskov]

Important study published. Leibovich and GRANT validated in ccRCC and non-ccRCC nationwide #kidneycancer cohort. Leibovich outperformed GRANT in predicting recurrence-free survival and should remain
standard approach to risk stratify patients. @oncoalert
https://t.co/GG09EPWzho

[Yüksel Ürün @DrYukselUrun]

Do we have a Litmus test to predict survival in localized kidney cancer?
🔸7653 patients: GRade, Age, Nodes, and Tumor score (GRANT) 🇩🇰
🔸Leibovich score outperformed the GRANT regarding RFS
@FDonskov @OncoAlert @Uroweb @urotoday @NessnAzawi @KidneyCancer
https://t.co/CLrsur2Dxq

[Frede Donskov @FDonskov]

Stong 5-yr data just published @KidneyCancer

[Yüksel Ürün @DrYukselUrun]

CheckMate 214
🔸Durable-long-term efficacy with Nivo-IPI
🔸mFU 67.7 months
🔸mOS: 55.7 months (48% @5Y)
🔸After 3 years the probability of remaining alive for an additional 2 years ↗️ with NIVO+IPI regardless of IMDC

@JournalCancer @OncoAlert @DrChoueiri
https://t.co/8Kj8lpIE0H